aricept Tab — Competitive Intelligence Brief

aricept Tab (aricept Tab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cholinesterase inhibitor. Area: Neurology.

phase 3 Cholinesterase inhibitor Acetylcholinesterase Neurology Small molecule

Target snapshot

aricept Tab (aricept Tab) — Icure Pharmaceutical Inc.. Aricept (donepezil) is a cholinesterase inhibitor that works by increasing the concentration of acetylcholine in the brain, which helps to improve cognitive function in patients with Alzheimer's disease.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
aricept Tab TARGET	aricept Tab	Icure Pharmaceutical Inc.	phase 3	Cholinesterase inhibitor	Acetylcholinesterase
Bloxiverz	NEOSTIGMINE	Fresenius Kabi	marketed	Cholinesterase Inhibitor	Acetylcholinesterase	2013-01-01
Razadyne	GALANTAMINE	Johnson & Johnson	marketed	Cholinesterase Inhibitor	Acetylcholinesterase	2001-01-01
Camptosar	onivyde	Pfizer	marketed	Topoisomerase Inhibitor	Acetylcholinesterase	1996-01-01
Camptosar	Irinotecan Hydrochloride	Pfizer	marketed	Topoisomerase Inhibitor	Acetylcholinesterase	1996-01-01
Zantac	ranitidine	GSK (originally Glaxo)	marketed	H2 receptor antagonist	Multidrug and toxin extrusion protein 1, Acetylcholinesterase, Histamine H2 receptor	1983-06-01
Lorfan	LEVALLORPHAN	Roche	marketed	levallorphan	Mu-type opioid receptor, Acetylcholinesterase, Mu-type opioid receptor	1982-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2027-01-06 — Camptosar · 8329213 · US
• 2027-01-06 — Camptosar · 8329213 · Compound · US
• 2028-08-29 — Camptosar · 8147867 · Compound · US
• 2028-08-29 — Camptosar · 8147867 · US
• 2033-06-12 — Camptosar · 9364473 · US
• 2033-06-12 — Camptosar · 9452162 · US
• 2033-06-12 — Camptosar · 9492442 · US
• 2033-06-12 — Camptosar · 9717724 · US
• 2033-06-12 — Camptosar · 9717724 · Method of Use · US
• 2033-06-12 — Camptosar · 9364473 · Method of Use · US
• 2033-06-12 — Camptosar · 12364691 · Method of Use · US
• 2033-06-12 — Camptosar · 11369597 · Method of Use · US
• 2033-06-12 — Camptosar · 9339497 · Method of Use · US
• 2033-06-12 — Camptosar · 9452162 · Method of Use · US
• 2033-06-12 — Camptosar · 9492442 · Method of Use · US
• 2033-06-12 — Camptosar · 10980795 · US
• 2033-06-12 — Camptosar · 11369597 · US
• 2033-06-12 — Camptosar · 9339497 · US
• 2033-06-12 — Camptosar · 10980795 · Method of Use · US
• 2036-08-19 — Camptosar · 11344552 · Method of Use · US
• 2036-10-15 — Camptosar · 10456360 · US
• 2036-10-15 — Camptosar · 10993914 · US
• 2036-10-15 — Camptosar · 12059497 · Formulation · US
• 2036-10-15 — Camptosar · 10456360 · Formulation · US
• 2036-10-15 — Camptosar · 10993914 · Formulation · US

Sponsor landscape (Cholinesterase inhibitor class)

1. Novartis · 3 drugs in this class
2. Eisai Co., Ltd. · 1 drug in this class
3. Icure Pharmaceutical Inc. · 1 drug in this class
4. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 1 drug in this class
5. Merck Sharp & Dohme LLC · 1 drug in this class
6. Pfizer · 1 drug in this class
7. Pontificia Universidade Catolica de Sao Paulo · 1 drug in this class
8. Singapore General Hospital · 1 drug in this class
9. Sunnybrook Health Sciences Centre · 1 drug in this class
10. Taipei Veterans General Hospital, Taiwan · 1 drug in this class